4//SEC Filing
Emerson Erik C. 4
Accession 0001710496-25-000002
CIK 0001894525other
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 6:37 PM ET
Size
6.1 KB
Accession
0001710496-25-000002
Insider Transaction Report
Form 4
Emerson Erik C.
DirectorChief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2025-10-15+215,000→ 215,000 totalExercise: $1.92Exp: 2035-10-15→ Common Stock, par value $0.01 per share (215,000 underlying)
Footnotes (1)
- [F1]The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.
Documents
Issuer
Apimeds Pharmaceuticals US, Inc.
CIK 0001894525
Entity typeother
Related Parties
1- filerCIK 0001710496
Filing Metadata
- Form type
- 4
- Filed
- Oct 16, 8:00 PM ET
- Accepted
- Oct 17, 6:37 PM ET
- Size
- 6.1 KB